Literature DB >> 1673331

Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.

M L Slovak1, M Coccia, P S Meltzer, J M Trent.   

Abstract

The molecular characteristics of two human doxorubicin-resistant cell lines were examined specifically for MDR1 gene amplification by Southern analysis and for overexpression of its messenger RNA. The 285-fold doxorubicin-resistant colon adenocarcinoma subline, LoVo/DR5, was found to overexpress the mRNA for P-glycoprotein without the concomitant requirement of MDR1 gene amplification, suggesting that relatively high levels of P-glycoprotein mediated multiple drug resistance may occur by transcriptional activation of the gene. Despite a similar in vitro selection strategy and in contrast to LoVo/DR cells, the 220-fold doxorubicin-resistant fibrosarcoma subline, HT1080/DR4, did not overexpress P-glycoprotein mRNA nor was the MDR1 gene amplified. In-gel renaturation studies were performed to determine the nature of a putative HSR-bearing chromosome 7 found in HT1080/DR4 cells; however, at a level of sensitivity nearing 20 copies of an amplified DNA fragment per haploid genome, no amplified sequences could be detected. These results suggest that doxorubicin resistance is multifactorial and alternative mechanisms of multiple drug resistance remain to be determined. LoVo/DR5 cells should prove to be a useful model for investigating transcriptional activation of the MDR1 gene; HT1080/DR4 cells should be an excellent model for the study of non-P-glycoprotein mediated multiple drug resistance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673331

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicine.

Authors:  M J Ruiz-Gómez; A Souviron; M Martínez-Morillo; L Gil
Journal:  J Physiol Biochem       Date:  2000-12       Impact factor: 4.158

Review 2.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 3.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

4.  Rapid detection, cloning and molecular cytogenetic characterisation of sequences from an MRP-encoding amplicon by chromosome microdissection.

Authors:  M E Ray; X Y Guan; M L Slovak; J M Trent; P S Meltzer
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.